What is spread pricing? Spread pricing is a contract option for employers and plan sponsors who want their pharmacy benefit company to carry the risk that pharmacies may charge different amounts for different drugs. Under this option, the employer or plan sponsor
Unlocking an Affordable Future Unlocking an Affordable Future NEWSROOM Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics NEWSROOM Alex Brill: Trends In The US Insulin Market: New Prices, New Players, New Dynamics Stop The
In case you missed it, last week’s RealClearPolitics’ virtual event, “The Consequences of Targeting Pharmacy Benefits,” featured policymakers and expert voices exploring the potential negative impact of policies being considered by Congress that target pharmacy benefit companies and market-based incentives
A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded
In case you missed it, business groups and individual employers from across the country signed the below letter to Congress expressing support for preserving their contracting flexibility and the protections provided by the Employee Income Security Act, ERISA. We appreciate
In case you missed it, JC Scott, president and CEO of the Pharmaceutical Care Management Association, discusses how recent proposals being considered by Congress targeting pharmacy benefits would increase health care costs at a time when premiums continue to rise
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s vote in the Senate Finance Committee to advance legislation impacting the Medicare Part D program and pharmacy benefit companies, or PBMs, that threatens to undermine
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) supports the Centers for Medicare and Medicaid Services’ (CMS) proposal to promote the use of biosimilars in Medicare Part D. Pharmacy benefit companies, or PBMs, have long supported the development of
©2024 PCMA. All Rights Reserved.
